Based in the United States, Eledon is a startup. Brouky records 1 investor associated with the company.
Eledon Pharmaceuticals develops tegoprubart, an anti-CD40L antibody designed to prevent organ transplant rejection by modulating the immune response, and is conducting global clinical trials focused on kidney and other organ transplants.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.